Glenmark launches Akynzeo I.V. in India for the prevention of chemotherapy induced nausea and vomiting

Glenmark launches Akynzeo I.V. in India for the prevention of chemotherapy induced nausea and vomiting

Akynzeo I.V., a fixed dose combination of fosnetupitant (235mg) and palonosetron (0.25mg), will be available as a single-dose, ready-to-dilute I.V. injection and it offers prevention from both acute and delayed phases of chemotherapy-induced nausea and vomiting

FPJ Web DeskUpdated: Monday, January 23, 2023, 10:34 AM IST
article-image
Glenmark launches Akynzeo I.V. in India for the prevention of chemotherapy induced nausea and vomiting | Image: Glenmark (Representative)

Glenmark Pharmaceuticals Ltd., global pharmaceutical company, announced the launch of a unique I.V. injection formulation, Akynzeo I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV),in India, the company said via an exchange filing.

The launch is under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.

Akynzeo I.V. is a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute I.V. injection.

It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV. The drug is already being marketed in the EU, the US, and Australia.

On the occasion of the launch, Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd., said, “At Glenmark, we are unwavering in our pursuit to help patients and clinicians in cancer care."

"Chemotherapy is the most common form of cancer treatment, with nausea and vomiting being two of its most debilitating side‐effects. Akynzeo I.V. is a convenient, single‐dose, ready‐to‐dilute I.V. injection that covers, both, the acute and the delayed phases of CINV, thereby enabling patients to avoid multiple antiemetic drugs, and improving compliance.”

Helsinn Group CEO, Giorgio Calderari, said, “Akynzeo I.V. would provide a new prophylactic option for patients in India, undergoing chemotherapy and who are at risk of CINV. We are delighted to partner with Glenmark who has an excellent footprint in this region and is trusted with providing the best treatment options for cancer patients.”

RECENT STORIES

Ecos (India) Mobility Submits Draft Paper To SEBI For IPO Fundraising

Ecos (India) Mobility Submits Draft Paper To SEBI For IPO Fundraising

How Data Is Enabling Innovation In Biomedical Devices For Healthier Lives

How Data Is Enabling Innovation In Biomedical Devices For Healthier Lives

Heralding Mediated Dispute Resolution Over Litigation: The Mediation Act, 2023, Future Of Indian...

Heralding Mediated Dispute Resolution Over Litigation: The Mediation Act, 2023, Future Of Indian...

Force Motors Shifts Gears: Exiting Tractors And Connected Activity Business At The End Of FY24

Force Motors Shifts Gears: Exiting Tractors And Connected Activity Business At The End Of FY24

'From Shop Floor To Success': Anand Mahindra Backs Elon Musk's Call For Recognition Of Manufacturing...

'From Shop Floor To Success': Anand Mahindra Backs Elon Musk's Call For Recognition Of Manufacturing...